Author Archives: David Melamed, PhD

STADA Acquires Triple Combo Pump Therapy, Seeks European Approvals

STADA Arzneimittel has announced the acquisition of Sweden-based Lobsor Pharmaceuticals, gaining the rights to its triple-combination therapy of levodopa, carbidopa, and entacapone, delivered via modern pump technology, as a treatment for patients with late-stage Parkinson’s disease. The triple-combo treatment has already been approved in most…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums